Clinical Trial Update: Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating AVP-786 as an adjunctive treatment for major depressive disorder in patients with inadequate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate)

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Depressive Disorder, Treatment-Resistant | Phase 2 | Status: COMPLETED